Scinovex
article Open AccessTop 1% cited

MicroRNA Expression Profiling in Human Ovarian Cancer: <i>miR-214</i> Induces Cell Survival and Cisplatin Resistance by Targeting <i>PTEN</i>

Cancer Research · 2008 · Vol. 68(2) · pp. 425–433
Hua YangWilliam KongLili HeJianjun ZhaoJoshua D. O’DonnellJiawang WangRobert M. WenhamDomenico CoppolaPatricia A. KrukSanto V. NicosiaJin Q. Cheng

Abstract

MicroRNAs (miRNA) represent a novel class of genes that function as negative regulators of gene expression. Recently, miRNAs have been implicated in several cancers. However, aberrant miRNA expression and its clinicopathologic significance in human ovarian cancer have not been well documented. Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster. Further, we show the frequent deregulation of miR-214, miR-199a*, miR-200a, and miR-100 in ovarian cancers. Significantly, miR-214 induces cell survival and cisplatin resistance through targeting the 3'-untranslated region (UTR) of the PTEN, which leads to down-regulation of PTEN protein and activation of Akt pathway. Inhibition of Akt using Akt inhibitor, API-2/triciribine, or introduction of PTEN cDNA lacking 3'-UTR largely abrogates miR-214-induced cell survival. These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.

MicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseasesPTENmicroRNAOvarian cancerCancer researchProtein kinase BBiologyCisplatinPI3K/AKT/mTOR pathwayCancerSignal transduction

MeSH terms

Antineoplastic AgentsBase SequenceCell SurvivalCisplatinFemaleHumansMolecular Sequence DataOvarian NeoplasmsRibonucleosidesSequence Homology, Nucleic AcidTumor Cells, CulturedSignal TransductionGene Expression Regulation, NeoplasticApoptosisDrug Resistance, Neoplasm

Funding

  • U.S. Department of Defense
  • Moffitt Cancer Center
  • National Institutes of Health
Citations
1,051
FWCI
35.53
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.